Aptagen, LLC
* The secondary structure may not be accurate because of MFOLD limitations on chemistries other than RNA/DNA.
Membrane-Bound IgM (TD05.17) (ID# 7717)
Chimeric
Membrane-bound IgM (mIgM )/ B-cell receptor (BCR )/ Leukemia / Lymphoma
Protein
43 nM (reported value)
Binding Buffer: RPMI 1640, 4.5 g/L glucose, 5 mM MgCl2 in vivo (20 mM MgCl2 in vitro), 100 mg/L tRNA and 100 mg/L BSA.
4°C
NA If the oligo is a known aptamer sequence: For binding studies, perform a refolding protocol to ensure proper function (i.e. binding to antigen or target). Refer to the aptamer reference source for the appropriate refolding parameters and binding conditions. Note: it is unknown whether aptamer functions properly without refolding.
Binds to Ramos and SKLY-16 cell lines and CLL and HCL clinical samples.
Variable binding to Daudi cell line.
Partial binding to normal B cells.
Variable binding to Daudi cell line.
Partial binding to normal B cells.
The monomer does not bind at 37°C (Kd > 10,000 nM). Aptamer was trimerized using PEG linkers. This increased the stability and binding affinity of the aptamer at higher temperatures (Kd = 256 nM at 37°C / Kd = 7.9).
This aptamer is a truncated version of TD05 below.
The four nucleotides at the 3'-tail were replaced with linked nucleic acids to strengthen the stem.
This aptamer is a truncated version of TD05 below.
The four nucleotides at the 3'-tail were replaced with linked nucleic acids to strengthen the stem.
5'-dApdGpdGpdApdGpdGpdApdTpdApdGp dTpdTpdCpdGpdGpdTpdGpdGpdCpdTp dGpdTpdTpdCpdApdGpdGpdGpdTpdCp dTpdCpdCpbTnbCnbCnbTn-3'
37
10256.7
349100
Note: Information on this aptamer oligo was obtained from the literature and hasn't been validated by Aptagen.
R Mallikaratchy et al. "A multivalent DNA aptamer specific for the B-cell receptor on human lymphoma and leukemia." Nucleic Acids Res. 39(2011): 2458-2469.
Have your aptamer oligo synthesized ORDER
We are always looking for ways to improve. Please tell us what you think.